LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- -
- Market Cap
- -
Clinical Trials
72
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (65 trials with phase data)• Click on a phase to view related trials
Effect of Colchicine on Progression of Known Coronary Atherosclerosis in Patients With Stable Coronary Artery Disease
- First Posted Date
- 2024-04-02
- Last Posted Date
- 2024-10-14
- Target Recruit Count
- 84
- Registration Number
- NCT06342609
- Locations
- 🇺🇸
Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center, Torrance, California, United States
Study of Cannabidiol in Sanfilippo Syndrome
- Conditions
- Sanfilippo SyndromeMucopolysaccharidosis III
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-03-27
- Last Posted Date
- 2025-03-19
- Target Recruit Count
- 35
- Registration Number
- NCT06333041
- Locations
- 🇺🇸
The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California, United States
Controlled Trial of Omadacycline Randomized Treatment Given for Bone and Joint Infection
- Conditions
- Bone InfectionJoint InfectionBone and Joint Infection
- Interventions
- Drug: Standard of Care
- First Posted Date
- 2023-03-03
- Last Posted Date
- 2025-03-10
- Target Recruit Count
- 180
- Registration Number
- NCT05753215
- Locations
- 🇺🇸
The Lundquist Institute For Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California, United States
Diet-induced Elevations in LDL-C and Progression of Atherosclerosis
- Conditions
- Hypercholesterolemia
- First Posted Date
- 2023-02-17
- Last Posted Date
- 2024-03-19
- Target Recruit Count
- 100
- Registration Number
- NCT05733325
- Locations
- 🇺🇸
Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center (The Lundquist Institute), Torrance, California, United States
Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT
- Conditions
- Type II DiabetesAtherosclerosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-02-01
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Matthew J. Budoff
- Target Recruit Count
- 120
- Registration Number
- NCT05708859
- Locations
- 🇺🇸
Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center (The Lundquist Institute), Torrance, California, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 15
- Next